By name: "KSB-D05-K0019" description: "Special Safety Considerations: Immunogenicity monitoring, drug-drug interaction studies, biomarker safety assessment..." version: "1.0.0" domain: "D05" domain_name: "Clinical Trials PV" type: "Knowledge" proficiency_level: "L4" bloom_level: "evaluate" triggers: - "explain special safety considerations" - "what is special safety considerations" - "evaluate special safety considerations" epa_mapping: "EPA-02, EPA-04, EPA-08" cpa_mapping: "CPA-01, CPA-07" regulatory_refs: "EMA-REG-004, ICH-E6"
KSB-D05-K0019: Special Safety Considerations
Overview
Domain: D05 - Clinical Trials PV Type: Knowledge Proficiency Level: L4 (Proficient - Independent practice) Bloom Level: Evaluate
Description
Immunogenicity monitoring, drug-drug interaction studies, biomarker safety assessment
Context
- Major Section: Clinical Trial Regulatory Framework and Safety Requirements
- Section: Comprehensive Safety Planning Framework
EPA Mapping
- EPA-02:3004-3005
- EPA-04:3009-3010
- EPA-08:3018-3019
CPA Pathway
- CPA-01, CPA-07
Regulatory References
- EMA-REG-004
- ICH-E6
Instructions
When this skill is activated, Claude should:
- Demonstrate L4 proficiency in special safety considerations
- Apply evaluate level cognitive skills to evaluate the topic
- Reference relevant regulatory guidance (EMA-REG-004, ICH-E6)
- Connect to related EPAs: EPA-02, EPA-04, EPA-08
Key Competencies
- Immunogenicity monitoring, drug-drug interaction studies, biomarker safety assessment
Assessment Criteria
- Can evaluate core concepts independently
- Demonstrates understanding of regulatory context
- Applies knowledge appropriately to PV scenarios
Related Skills
- Other D05 skills in Comprehensive Safety Planning Framework
- Cross-domain integrations per DAG architecture
Generated from PV KSB Framework v1.0 | 2025-12-31